Meeting
2023 ASCO Annual Meeting
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.
Authors
Yufan Liu
United States Food and Drug Administration, Silver Spring, MD
Yufan Liu , Elizabeth Duke , Nicole Lauren Drezner , Harpreet Singh , Paul Kluetz , Richard Pazdur , Erin A. Larkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9119)
DOI
10.1200/JCO.2023.41.16_suppl.9119
Abstract #
9119
Poster Bd #
107
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world (rw) analysis of quantitative MET copy number (CN) as a biomarker in NSCLC.
First Author: David Chun Cheong Tsui
Poster
2022 ASCO Annual Meeting
A real-world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD).
First Author: Nathan A. Pennell
Poster
2021 ASCO Annual Meeting
Impact of immune checkpoint inhibitor (CPI) and EGFR tyrosine kinase inhibitor (TKI) sequence on time to treatment failure (TTF) among EGFR plus NSCLC treated in a community-based cancer research network.
First Author: Carissa Jones
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly